Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center Randomized Controlled Study of High/Low-dosage Rivaroxaban Compared With DAPT After Left Atrial Appendage Occulsion in Patients With Non-valvular Atrial Fibrillation (ESCORT-AF Study(B)

Next Previous
Search
Trial Profile

A Multi-center Randomized Controlled Study of High/Low-dosage Rivaroxaban Compared With DAPT After Left Atrial Appendage Occulsion in Patients With Non-valvular Atrial Fibrillation (ESCORT-AF Study(B)

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel
  • Indications Thrombosis
  • Focus Therapeutic Use
  • Acronyms ESCORT-AF

    • Most Recent Events

    • 10 Nov 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm decreases from 3 to 2, the planned patient number increases from 600 to 826. Study design changed from open label to triple blind. Time frame of primary endpoint changed from 3 months to 24 weeks
    • 10 Nov 2022 Planned End Date changed from 30 Nov 2020 to 30 Oct 2024.
    • 10 Nov 2022 Planned primary completion date changed from 30 May 2020 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top